Amphista Therapeutics: Series B Financing

“The team at Scius have been an invaluable support during such a pivotal year for us. They have deep expertise in supporting companies through financing announcements and effectively co-ordinated with our key stakeholders. We were delighted by the coverage achieved in the major trade publications.”

Nicola Thompson, CEO of Amphista Therapeutics

Objectives

Promote Amphista as a pioneer and global leader in the TPD space
Highlight the experience of the world class leadership team
Raise awareness of the rapid progress from a $7.5m Series A to a $53m Series B in under a year, including a broad range of leading life-science and corporate investors in an oversubscribed round.

Strategy

Liaising with the key stakeholders, including several investors, involved in the Series B to co-ordinate timings, sign-off and quotes for the announcement
Drafting announcement, key messages and QA and co-ordinating with stakeholders
Pre-briefing target journalists under embargo and setting up one-on-one briefings in advance of the news, with further media follow up on day of release

Results

Extensive global trade media coverage (BioCentury, BioWorld, and Endpoints), as well as local press in Scotland including The Herald, The Times, Daily Business, and The Scotsman.